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enhanced chemiluminescence; eYFP, enhanced yellow fluorescent protein; GPCR, G protein-
coupled receptor; Rluc, Renilla luciferase; TBST, Tris-buffered salt plus Tween 20 
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Abstract 
It is established that long-chain free fatty acids including ω-3 fatty acids mediate an array of 
biological responses through members of the free fatty acid receptor family, which includes 
FFA4. However, the signalling mechanisms and modes of regulation of this receptor class 
remain unclear. Here we employ mass spectrometry to determine that phosphorylation of mouse 
(m)FFAR4 occurs at five serine and threonine residues clustered in two separable regions of the 
C terminal tail, designated cluster 1 (Thr347, Thr349 and Ser350) and cluster 2 (Ser357 and Ser361). 
Mutation of these phospho-acceptor sites to alanine completely prevented phosphorylation of 
mFFA4 but did not limit receptor coupling to ERK1/2 activation. Rather an inhibitor of Gq/11 
proteins completely prevented receptor signalling to ERK1/2. In contrast, the recruitment of 
arrestin 3, receptor internalization and activation of Akt were regulated by mFFA4 
phosphorylation. The analysis of mFFA4 phosphorylation-dependent signalling was extended 
further by selective mutations of the phospho-acceptor sites. Mutations within cluster 2 did not 
affect agonist activation of Akt but instead significantly compromised receptor internalization 
and arrestin 3 recruitment. Distinctly, mutation of the phospho-acceptor sites within cluster 1 had 
no effect on receptor internalization and a less extensive effect on arrestin 3 recruitment, but 
significantly uncoupled the receptor from Akt activation. These unique observations define 
differential effects on signalling mediated by phosphorylation at distinct locations. This hallmark 
feature supports the possibility that the signalling outcome of mFFA4 activation can be 
determined by the pattern of phosphorylation (phosphorylation barcode) at the C-terminus of the 
receptor.  
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Introduction 
Rather than acting simply as sources of energy, in recent times fatty acids derived from 
the diet have been appreciated to also act as signalling molecules that play integrative roles in 
dietary homeostasis (Dranse et al., 2013; Hara et al., 2014; Offermanns, 2014). Key 
contributions of such fatty acids to metabolic and inflammatory control, and to dysregulation of 
processes that are associated with obesity and metabolic syndrome (Oh et al., 2014; Sekiguchi et 
al., 2015; Watterson et al., 2014), are produced via specific interactions with G protein-coupled 
receptors (GPCRs) present at the surface of cells within tissues, including the gut, pancreas and 
adipose tissue, that control metabolite distribution, flux and storage (Oh et al., 2014; Sekiguchi et 
al., 2015; Watterson et al., 2014). Two GPCRs, FFA1 (also known as GPR40) and FFA4 (also 
known as GPR120) are known to respond selectively to longer chain free fatty acids (Milligan et 
al., 2015). FFA1 is highly expressed by pancreatic β-cells (Mancini and Poitout, 2013) and plays 
a key role in stimulating release of insulin in a glucose-concentration-dependent manner 
(Mancini and Poitout, 2013). This receptor has attracted considerable attention as a means to 
control glucose homeostasis and, therefore, as a potential therapeutic target for the treatment of 
type II diabetes (Mancini and Poitout, 2013). Indeed, the FFA1 agonist fasiglifam entered phase 
III clinical trials but, although clearly able to regulate glycaemia and to produce clinically 
relevant lowering of HbA1c levels in type II diabetes patients (Kaku et al., 2015; Mancini and 
Poitout, 2013; Mancini and Poitout, 2015), it was withdrawn from further trials over concerns of 
possible liver toxicity. Whilst FFA4 is also expressed in the pancreas (Stone et al., 2014; Suckow 
et al., 2014), where it may play roles in the regulation of glucagon production (Suckow et al., 
2014), it is also expressed in various enteroendocrine cells (Iwasaki et al., 2015; Liu et al., 2015; 
Parker et al., 2009), in adipocytes (Liu et al., 2015; Oh et al., 2010; Oh et al., 2014) and 
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macrophages (Im, 2015; Liu et al., 2015; Oh et al., 2010; Oh et al., 2014).  Potential 
combinations of effects on the release of incretins and/or satiety-regulating hormones in the gut, 
differentiation of and uptake of glucose by adipocytes, and control of the release of inflammatory 
mediators by macrophages, has suggested that FFA4 might also be a useful therapeutic target to 
modulate insulin resistance and glucose homeostasis (Ichimura et al., 2014; Liu et al., 2015; 
Milligan et al., 2015; Oh et al., 2014). A non-synonymous polymorphic variant of FFA4 has 
been reported to be linked to obesity in man (Ichimura et al., 2012), however, this variant does 
not appear to be linked to risk of type II diabetes or variation of fasting insulin levels (Bonnefond 
et al., 2015). However, genetic elimination of FFA4 in mouse has been noted to result in obesity, 
glucose intolerance and fatty liver with decreased adipocyte differentiation when such animals 
are fed a high-fat diet (Ichimura et al., 2012). 
Murine models of diabetes and obesity make important contributions to pre-clinical 
predictions and decisions regarding possible therapeutic approaches. Therefore, understanding 
details of the responsiveness, function and regulation of murine (m)FFA4 in response to both 
endogenously generated and synthetic ligands (Oh et al., 2014), and how these may vary 
compared to the human receptor is vital. Herein we address these issues by exploring both G 
protein-dependent and -independent signals produced by mFFA4, defining sites of regulatory 
phosphorylation on the receptor and by generating and employing phospho-site specific 
antibodies that can define the intrinsic activity state of the receptor in situ. In this way we 
describe here the signalling responses that are regulated by mFFA4 phosphorylation within two 
clusters of phospho-acceptor sites at the C-terminal tail of the receptor.  
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Materials and Methods 
Materials   
Unless otherwise stated, all biochemicals and reagents were from Sigma-Aldrich Co. 
(Dorset, UK). Tissue culture reagents and buffers were from Life Technologies Inc. (Paisley, 
UK). Primers were purchased from Thermo Fisher Scientific (Ulm, Germany). TUG-891 (3-(4-
((4-fluoro-4′-methyl-[1,1′-biphenyl]-2-yl)methoxy)phenyl)-propanoic acid) was synthesized as 
described previously (Shimpukade et al., 2012). Compound 39 was synthesized according to 
Sparks et al., (Sparks et al., 2014). This compound is also known as AH 7614 and can be 
purchased from Tocris. The Gq/G11 inhibitor YM-254890 was a kind gift of Astrellas Pharma 
Inc. (Osaka, Japan). Cellular signalling assay kits (pAkt-Ser473, pERK1/2) were obtained from 
Cisbio Bioassays (Codolet, France). Antibodies (pAkt-Ser473, pERK1/2 and total ERK1/2) were 
obtained from Santa Cruz Biotechnology Inc (Heidelberg, Germany). Anti-GFP mouse 
monoclonal and anti-GFP rabbit polyclonal antibodies were purchased from Abcam (Cambridge, 
UK). Protease and phosphatase inhibitor cocktails were from Roche Applied Science (Burgess 
Hill, UK). [32P]-orthophosphate (5 mCi, 185 MBq) was from PerkinElmer. Enhanced 
chemiluminescence (ECL) developing reagent was from Millipore (Watford, UK). Protein A 
sepharose beads, ECL and X-ray films were obtained from GE Healthcare (Amersham, 
Buckinghamshire, UK). Xograph compact x2 film developer and developing solutions were 
obtained from Xograph Healthcare (Gloucestershire, UK). 
Plasmids and mutagenesis- To generate an HA epitope-tagged form of mFFA4, the 
receptor coding sequence was amplified by PCR that incorporated the HA tag sequence at the C-
terminal end followed by a stop codon.  The mFFA4 receptor was also fused at its C-terminus to 
enhanced yellow fluorescent protein (eYFP) and to an N-terminal FLAG epitope in 
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pcDNA5/FRT/TO. This construct was used as template to generate various mutants (see Results) 
using the Quickchange II method (Stratagene, UK). The identity of all new constructs generated 
was verified by nucleotide sequencing. Bovine arrestin 3 was fused to Renilla luciferase (Rluc) 
as previously described (Hudson et al., 2014; MacKenzie et al., 2014). 
Cell lines- Flp-InTM T-RExTM 293 cells able to express constructs of interest from the 
tetracycline/doxycycline T-RExTM -inducible locus were generated by co-transfecting FLAG-
mFFA4-eYFP or one of the mutants (FLAG-mFFA4-TDTS-AAA-eYFP, FLAG-mFFA4-
ADAA-SSS-eYFP or FLAG-mFFA4-ADAA-AAA-eYFP)  with the pOG44 plasmid into 
parental Flp-InTM T-RExTM 293 cells (Life Technologies Inc, Paisley, UK). Following 
transfection, 200 μg.ml-1 of hygromycin B was added to the culture medium allowing for 
polyclonal selection of cells. Chinese hamster ovary (CHO) cells which stably and constitutively 
expressed the non C-terminally tagged, C-terminal HA or eYFP epitope-tagged mFFA4 or 
mFFA4 containing mutations within the C-terminal tail were generated using the Flp-InTM 
system. CHO Flp-InTM cells (Life Technologies Inc) were co-transfected with pcDNA5/FRT 
containing mFFA4 and pOG44, transfected cells were selected with 400 µg/ml hygromycin B 
and expression of mFFA4 was confirmed by immunoblotting with anti-HA or anti-GFP 
antibody.   
[32P]-Orthophosphate labelling and mFFA4 immunoprecipitation- CHO Flp-InTM cells 
expressing mFFA4 were seeded at 200.000 cells/well in 6-well plates and grown for 48 h. They 
were then serum starved overnight at 37oC. Cells were washed three times in 1 ml phosphate free 
Krebs/HEPES buffer (10 mM HEPES, 118 mM NaCl, 4.69 mM KCl, 1.18 mM MgSO4.7H2O, 
1.3 mM CaCl2, 25.0 mM NaHCO3, 11.7 mM glucose, pH 7.4) and then incubated with 100 
μCi/ml [32P]-orthophosphate for 1.5 h at 37oC. Cells were treated with ligands for an appropriate 
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time at 37oC. The reactions were terminated by rapid aspiration of the buffer followed by 
addition of 1 ml ice-cold radioimmunoprecipitation (RIPA) buffer (10 mM Tris, 2 mM EDTA, 
20 mM glycerol-2-phosphate, 160 mM NaCl, 1% v/v Nonidet-P40, 0.5% w/v sodium 
deoxycholate, pH 7.4) for 30 min on ice. Cell lysates were cleared by centrifugation (20000 x g 
for 10 min) and receptors were immunoprecipitated from pre-cleared lysates using 1 μg/sample 
of the appropriate antibody for 1 h or overnight at 4oC. Immunocomplexes were isolated on 
protein A-sepharose beads and the beads were washed three times with ice-cold buffer (10 mM 
Tris, 2 mM EDTA, 20 mM glycerol-2-phosphate, pH 7.4). Immunocomplexes were resuspended 
in 2x SDS-PAGE sample buffer (125 mM Tris, 200 mM dithiothreitol, 4% SDS, 20% glycerol 
and 0.05% bromophenol blue, pH 6.8) and placed in a 60oC water bath for 3-5 min. Receptor 
proteins were resolved on 10% SDS-PAGE gels (200v, 1 h 20 min) and electroblotted onto 
nitrocellulose membranes using the semi-dry transfer method and Tris-Glycine transfer buffer 
(25 mM Tris, 190 mM Glycine, 20% methanol). Receptor phosphorylation was detected on X-
ray films and developed using Xograph film developer. The films were scanned and bands were 
quantified using AlphaImager software (Alpha Innotech, San Leandro, CA). Parallel western 
blotting was performed on the immunoprecipitated samples to check for loading consistency.  
mFFA4 purification and mass spectrometry- Cells were stimulated with 10 µM TUG-891 
for 5 min at 37oC and then harvested using PBS/1 mM EDTA (pH 7.4). Membranes were 
prepared and receptors were solubilized in PBS/1% NP-40 supplemented with protease and 
phosphatase inhibitors for 4 h at 4oC. Samples were centrifuged (20000 x g, 20 min) and the 
receptors in the supernatant were immunoprecipitated using anti-HA antibody coupled to agarose 
beads. The purified receptors were resolved on 8% SDS-PAGE gel and the gel was stained with 
colloidal Coomassie blue to reveal receptor band(s). The bands were excised and cut into 1-2 
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mm squares and then incubated with 1 μg sequencing grade trypsin (Promega, Southampton, 
UK) in 50 mM ammonium bicarbonate overnight at 37oC. The supernatant was transferred to 
fresh tubes and the gel pieces were washed twice with 0.1% trifluoroacetic acid dissolved in 50% 
acetonitrile. The supernatants were pooled and subjected to LC MS/MS analysis. 
LC-MS/MS was carried out using an LTQ Orbitrap mass spectrometer (Thermofisher Scientific, 
Rockford, IL). The pooled supernatants containing receptor peptides were loaded at high flow 
rate onto a reverse-phase trapping column (0.3mm i.d. x 1mm), containing 5µm C18 300 Å 
Acclaim PepMap media (Dionex, UK) and eluted through a reverse-phase capillary column 
(75µm i.d. x 150mm) containing Symmetry C18 100 Å media (Waters, Elsetree, U.K.) that was 
self-packed using a high pressure packing device (Proxeon Biosystems, Odense, Denmark). The 
resulting spectra were searched against the UniProtKB/SwissProt database using MASCOT 
(Matrix Science Ltd.) software with peptide tolerance set to 5 ppm and the MS/MS tolerance set 
to 0.6 Da. Fixed modifications were set as carbamidomethyl cysteine with variable modifications 
of phospho-serine, phospho-threonine, phospho-tyrosine and oxidized methionine. The enzyme 
was set to Trypsin/P and up to 2 missed cleavages were allowed.  Peptides with a Mascot score 
greater than 20 and where the probability P that the observed match was a random event was 
<0.05 were included in the analysis. The spectra of peptides reported as being phosphorylated 
were interrogated manually to confirm the precise sites of phosphorylation.    
Generation of phosphorylation-site specific FFA4 antisera- Phosphorylation specific 
antisera were raised against two peptides; IFTDTS(P)VRRNDLNDLS and 
GAIFT(P)DTS(P)VRRND, which correspond to amino acids 343–357 of mFFA4 in which Ser350 
was phosphorylated in the first peptide and Thr347 and Ser350 were phosphorylated in the second 
peptide. The 87-day program, which included four immunizations, was performed by Eurogentec 
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(Leige Science Park, Seraing, Belgium). The resulting antiserum was purified against the 
immunizing peptide. 
Antibody characterization using phosphatase treatment- To characterize potential 
phospho-specific antibodies, phosphatase treatment experiments were performed. Cells seeded at 
200 000 cells/well in 6-well plates were grown for 48h at 37oC and then serum starved overnight 
at 37oC. Cells were stimulated with an agonist and the receptors were purified by 
immunoprecipitation as described above. The immunoprecipitated receptors were washed 3 x 
150 μl with calf intestinal alkaline phosphatase (CIAP) buffer supplemented with protease 
inhibitors and 0.2% octyl glucoside. The beads were resuspended in 50 μl CIAP buffer in the 
presence of 40 U CIAP and incubated overnight at 37oC. Positive controls which consist of 
immunoprecipitated receptors incubated in CIAP buffer were included. The CIAP buffer was 
aspirated and the beads were resuspended in SDS-PAGE sample buffer. Samples were run on 
8% SDS-PAGE and analysed by western blotting. 
Immunocytochemistry- CHO cells expressing FLAG-mFFA4-eYFP tagged receptors 
were seeded onto 20-mm glass coverslips for 48 h prior to experimentation. Cells were serum 
starved overnight at 37oC and then treated with vehicle, the FFA4 antagonist compound 39 or 
agonist for the indicated time. Cells were fixed in PBS containing 4% paraformaldehyde for 30 
min at room temperature. Phosphorylation specific antibody pThr347/pSer350 was used at 0.52 
ng/ml followed by Alexa FluorTM 546 goat anti-rabbit secondary antibody at 1:1000 dilution. 
Data were acquired using an LSM510 laser-scanning confocal microscope (Zeiss). 
mFFA4-arrestin 3 interaction assay- Arrestin 3 recruitment to mFFA4 was assessed 
using a bioluminescence resonance energy transfer (BRET) assay (Butcher et al., 2014; Hudson 
et al., 2014; Jenkins et al., 2010; MacKenzie et al., 2014). Briefly, HEK293T cells were co-
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transfected with arrestin 3-Rluc and eYFP-tagged receptor plasmids in a 1:4 ratio using 
polyethyleneimine. After 24 h incubation, cells were sub-cultured into poly-D-lysine coated 
white 96 well microplates and incubated for a further 24 h prior to the assay. Cells were washed 
and incubated in Hanks’ Balanced Salts Solution for 30 min prior to conducting the assay. The 
luciferase substrate coelenterazine h (2.5 μM) (Nanolight Tech, Pinetop, CA) was added to the 
cells and incubated for 10 min at 37°C before test compounds were added. Following a further 5 
min incubation at 37°C, luminescent emissions at 535 and 475 nm were measured using a 
PHERAstar FS (BMG Labtech, Aylesbury, UK). BRET signals were represented as the 535/475 
ratio and for all mutant forms of mFFA4 the BRET ratios obtained were expressed as a 
percentage of the maximum ratio obtained for TUG-891 at the wild type receptor. Kinetic 
experiments of arrestin-3 recruitment were carried out on transiently transfected HEK293T cells 
by incubating the cells at 37°C in the PHERAstar FS after addition of 5 μM coelenterazine h, 
with BRET measurements taken at 6 s intervals. In these experiments, test compounds were 
added using PHERAstar FS injectors allowing for continuous measurement during and 
immediately following compound addition. 
Visualization of mFFA4 Internalization- Flp-InTM T-RExTM 293 cells expressing the 
different mutant constructs were cultured on poly-D-lysine coated glass coverslips and cultured 
for 24 hours before treatment with doxycycline (100 ng.ml-1) to induce receptor expression. Live 
cells were then imaged using a Zeiss VivaTome spinning disk confocal microscopy system (Karl 
Zeiss, Oberkochen, Germany). Images were taken before the addition of ligand, and every 5 
minutes after ligand addition for a total of 60 minutes. 
Cell Surface Enzyme-Linked Immunosorbent Assay (ELISA)- Flp-InTM T-RExTM 293 cells 
expressing the different constructs were cultured on poly-D-lysine coated flat bottom 96-well 
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plates for 24 hours before treatment with doxycycline (100 ng.ml-1) and treated with ligand for 
the indicated times. Total receptor surface expression was measured on paraformaldehyde fixed 
cells. These were subsequently incubated in PBS containing 5% bovine serum albumin (BSA) to 
block nonspecific binding sites (30 minutes at room temperature), followed by incubation with 
an anti-FLAG monoclonal primary antibody (30 minutes at room temperature), and finally with 
an anti-mouse horseradish peroxidase conjugated secondary antibody (30 minutes at room 
temperature). Cells were washed 3 times with PBS before measuring Hoechst fluorescence using 
a PolarStar Omega plate reader (BMG Labtech, Offenburg, Germany). After washing a final 
time with PBS, and incubating with 3,3’,5,5’-tetramethylbenzidine horseradish peroxidase 
substrate in the dark at room temperature, the absorbance at 620 nm was measured on a PolarStar 
Omega plate reader. To calculate surface expression, the 620 nm absorbance was corrected for 
cell number based on Hoechst fluorescence. 
Akt(Ser473) phosphorylation assay- mFFA4 signalling to phospho-Akt Ser473 (also called  
protein kinase B) was detected by using the HTRF phospho-Akt (Ser473) kit (Cisbio Biassays, 
Codolet, France). In brief, cells were seeded in 96 well plates at 20000 cells/well and grown for 
48 hrs before being serum starved overnight at 37oC. Cells were stimulated with an agonist for 
the indicated times and lysed with 50 µl of lysis buffer for 1 hr at RT. Lysates (16 µl) were 
transferred to 384 well plates and 4 µl of premixed d2/cryptate antibodies (1:1 v/v) were added 
to each lysate. The reaction mixtures were incubated for 2 hr at RT and the plate was read on the 
ClarioStar plate reader (BMG Labtech, Aylesbury, UK). For inhibition experiments, cells were 
treated with an inhibitor (Gαq/11 inhibitor/pertussis toxin) for the indicated time before the 
addition of the agonist. Confirmatory assays were performed using western blotting with total 
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and phospho-Akt (Ser473) antibody purchased from Santa Cruz Biotechnology Inc (Heidelberg, 
Germany). 
ERK1/2 phosphorylation assay- Receptor-mediated ERK1/2 phosphorylation was 
determined by using the Cisbio HTRF phospho-ERK (Thr202/Tyr204) cellular assay kit in a 
protocol identical to the phospho-Akt assay above.  
Immunoblotting- Nitrocellulose membranes containing resolved receptor proteins were 
incubated in blocking solution (20 mM Tris, 150 mM NaCl, 0.1% Tween-20 (TBST), 5% non-fat 
dried milk, pH 7.5) for 1 h at room temperature or overnight at 4oC. Membranes were probed 
with the appropriate primary antibody (diluted in blocking solution) for 1 h at RT. Membranes 
were washed 3 x 15 min in TBST and then incubated with a secondary antibody (diluted in 
blocking solution) for 1 h at RT. Following 3 x 15 min washes in TBST the membranes were 
dried by blotting the edge onto a piece of tissue paper. The membranes were placed on glass 
plates and ECL developing reagent was added for 5 min. Immunoreactivity was captured on 
ECL films and developed using a Xograph film developer. The films were scanned and bands 
were quantified using AlphaImager software (Alpha Innotech, San Leandro, CA). 
Data analysis- All data presented represent mean ± standard error of at least three 
independent experiments. Data analysis and curve fitting was carried out using the Graphpad 
Prism software package. Concentration-response data were fitted to three-parameter sigmoidal 
concentration-response curves. Statistical analyses were carried out using standard t-tests, 1-way 
analysis of variance with Tukey’s post-hoc analysis, or 2-way analysis of variance combined 
with Bonferonni post-hoc analysis as appropriate. 
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Results 
Murine FFA4 becomes phosphorylated in an agonist-dependent fashion- To investigate if 
the murine (m)FFA4 receptor becomes phosphorylated in an agonist-dependent manner we 
performed [32P]-orthophosphate labelling of CHO Flp-InTM cells stably expressing a form of 
mFFA4 that incorporated a C-terminal HA-epitope tag (mFFA4-HA). Subsequent to treatment of 
the cells with either vehicle, an ω-3 fatty acid agonist (α-linolenic acid (αLA, 100 μM)) or the 
synthetic FFA4 agonist TUG-891 (10 μM, Figure 1), samples were immunoprecipitated with 
anti-HA antibody, resolved by SDS-PAGE and exposed to X-ray film. Under basal conditions, 
[32P] was incorporated predominantly into a polypeptide with molecular mass of ~45kDa 
(Figure 1A) which correlated with the molecular mass of the mFFA4 construct as determined in 
anti-HA immunoblots (Figure 1B). The extent of incorporation of the radiolabel was 
significantly increased in samples that had been exposed to either αLA or TUG-891 (Figure 
1C). Global incorporation of [32P] in response to treatment with TUG-891 was rapid, peaking 
within 3 minutes (Figure 1D).  Although showing a tendency to decline, TUG-891-induced 
phosphorylation remained significantly elevated over vehicle treatment for at least 30 minutes 
(Figures 1D-1F). These data indicate that mFFA4 is phosphorylated in the basal state and 
undergoes a rapid and sustained increase in phosphorylation following agonist stimulation.   
Agonist-mediated phosphorylation occurs within two clusters of residues within the 
intracellular C-terminal tail of mFFA4- To identify specific amino acids that became 
phosphorylated in response to TUG-891 we performed mass spectrometry. Phosphorylation of 
wild type mFFA4-HA was detected at multiple residues in these studies (Figure 2). We obtained 
excellent coverage of the intracellular domains of mFFA4 with identification of tryptic peptides 
containing more than 70% of the serine and threonine residues contained within the intracellular 
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loops and C-terminal tail. All the phosphorylation sites identified were within the C-terminal tail 
and appeared in two spatially resolved clusters. Cluster 1 contained phosphorylation sites on 
residues Thr347, Thr349 and Ser350 and cluster 2 contained sites on Ser357 and Ser361. Hence, five 
out of six serine/threonine residues in the C-terminal tail were phosphorylated. Despite 
identifying peptides containing the one remaining serine in this region there was no evidence 
from mass spectrometry that this residue, Ser360, was phosphorylated.  
Antisera generation and characterization- To further characterize the phosphorylation 
status of mFFA4 and its regulation we generated antisera predicted to specifically identify 
phosphorylation of both Thr347 and Ser350 of the receptor, or only of Ser350. These residues were 
selected on the basis that phosphorylation at these amino acids was readily observed in the mass 
spectrometry studies and phospho-peptides containing these sites were predicted to be highly 
immunogenic. Following anti-GFP/eYFP immunoprecipitation of lysates from Flp-InTM CHO 
cells expressing a form of mFFA4 incorporating an N-terminal FLAG-epitope tag and C-
terminal yellow fluorescent protein (eYFP) (FLAG-mFFA4-eYFP) and that that had been treated 
with TUG-891, immunoblotting with either pThr347/pSer350 or pSer350 antibodies detected a ~80 
kDa polypeptide that potentially reflected the appropriately phosphorylated form of the receptor 
(Figures 3A, 3B).  Confirmation that the antibodies specifically identified phosphorylated forms 
of FLAG-mFFA4-eYFP was provided by pre-treatment of the samples with calf intestinal 
alkaline phosphatase (CIAP), to remove phosphate groups, prior to resolution by SDS-PAGE 
where neither pT347/pS350 nor pS350 antisera were able to identify the FLAG-mFFA4-eYFP 
protein (Figures 3A, 3B). Immunoblots using an anti-GFP antiserum demonstrated the presence 
of similar levels of receptor protein in all samples (Figure 3C). Importantly, even without the 
immuno-enrichment provided by anti-GFP/eYFP immunoprecipitation the pThr347/pSer350 and 
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pSer350 antisera were both able to detect phosphorylated FLAG-mFFA4-eYFP in lysates of cells 
expressing the receptor construct and, as anticipated, recognition was enhanced substantially 
following treatment of the cells with TUG-891 (Figures 3D-3F).  
Furthermore, the pThr347/pSer350 antibody was able to detect mFFA4 receptor 
phosphorylation in the presence and absence of C-terminal tail eYFP tag (Supplementary 
Figure 1). This suggests that at least for these two sites, the presence of eYFP tag at the C-
terminal tail does not interfere with receptor phosphorylation.    
Interestingly, although murine and human share a high degree of sequence similarity 
within the C-terminal tail, they are not identical. In particular, the epitope recognised by the 
antibodies in the mouse and human FFA4 receptors differ by two amino acid residues (mouse; 
GAIFTDTSVRRNDLS and human; GAILTDTSVKRNDLS). Neither the mFFA4 
pThr347/pSer350 nor mFFA4 pSer350 antibodies were able to identify human FLAG-FFA4-eYFP 
that had been phosphorylated by treatment with TUG-891 (Figures 3D-3F). The phospho-
specific antibodies therefore displayed exquisite species selectivity, as previously also noted for 
equivalent phospho-specific antibodies to human FFA4 (Butcher et al., 2014). Phosphorylation 
of mFFA4 in response to TUG-891 as detected by the pThr347/pSer350 antibodies was 
concentration-dependent (Figure 4A). Moreover, this effect of TUG-891 was blocked by co-
addition of the FFA4 antagonist, compound 39 (Sparks et al., 2014) (Figure 4B, 4D) and this 
was also true for identification using the mFFA4 pSer350 antiserum (Figure 4B).  As well as 
phosphorylation of mFFA4 by the synthetic agonist, activation of mFFA4 with either of the ω-3 
fatty acids, α-linolenic acid (αLA) or docosahexaenoic acid (DHA) also resulted in 
phosphorylation of the receptor as detected by the pThr347/pSer350 antiserum in a time-dependent 
and sustained fashion (Figure 4C).  
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The pThr347/pSer350 antibodies were also capable of identifying TUG-891-activated 
mFFA4 in immunocytochemical studies. In Flp-InTM CHO cells expressing FLAG-mFFA4-
eYFP these antibodies illuminated the plasma membrane of agonist-treated cells and merging of 
images of the antibody staining with those of the location of the eYFP tag showed co-incidence 
(Figure 5A). pThr347/pSer350 antibody staining was substantially less intense in vehicle-treated 
cells (Figure 5B) and cell surface staining was completely abolished in cells that had been pre-
treated with the antagonist compound 39 (Figure 5C). These data, coupled with a lack of 
significant antibody staining of non-transfected cells (Figure 5D), indicated the specificity of the 
antibody recognition of the phosphorylated form(s) of the receptor (Figure 5). 
Generation of phosphorylation-deficient mFFA4 variants- To define whether residues 
identified as being phosphorylated in the mass spectrometry studies played important roles in 
potential interactions between mFFA4 and arrestin 3, we generated a series of site-directed 
mutants of the receptor.  [32P]-orthophosphate labelling experiments were performed in Flp-InTM 
CHO cells stably expressing either the wild type FLAG-mFFA4-eYFP construct or receptor 
variants that had been mutated to convert various serine and/or threonine residues to alanine 
(Figure 6A). Consistent with the data from mFFA4-HA (Figure 1), the wild type construct, 
which due to the eYFP tag compared with the HA-tagged receptor in Figure 1 now migrated as a 
~75kDa polypeptide, showed basal levels of phosphorylation in [32P]-orthophosphate labelling 
experiments that significantly increased with agonist (TUG-891) stimulation (Figure 6B). The 
two clusters of serine/threonine phosphorylation sites identified by mass spectrometry (cluster 1: 
amino acids 347-350 and cluster 2: 357-361) were altered as either two separate groups or the 
two sets of mutations were combined to eliminate all the potential sites of phosphorylation 
(Figure 6A). The variant in which serine and threonine residues within cluster 1 (347TDTS350) 
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were replaced with alanine (designated mFFA4-ADAA-SSS) was substantially less 
phosphorylated upon addition of TUG-891 (Figure 6B). Similarly, the variant (designated 
mFFA4-TDTS-AAA), in which the serine residues within cluster 2 (Ser357, Ser360 and Ser361) 
were replaced with alanine, also showed substantially lower incorporation of [32P] following 
addition of TUG-891 (Figure 6B). Combination of these two groups of alterations produced a 
form of the receptor (mFFA4-ADAA-AAA) in which both basal and agonist-induced 
phosphorylation was absent (Figure 6B). This was despite this form of the receptor being 
expressed as well as wild type and the other two mutants (Figure 6C). The level of agonist-
mediated phosphorylation of mFFA4-ADAA-SSS was similar to that of mFFA4-TDTS-AAA 
(Figure 6D), suggesting both clusters of Ser/Thr residues contribute to a similar extent to the 
phosphorylation capacity of mFFA4 in response to TUG-891. These phospho-acceptor variants 
also confirmed the specificity of the pT347/pS350 antiserum.  Immunoblots performed on 
lysates from Flp-InTM T-RExTM 293 cells stably expressing eYFP tagged versions of each of the 
three mutants showed a lack of recognition of both mFFA4-ADAA-AAA and mFFA4-ADAA-
SSS, either with or without treatment with TUG-891 (Figure 6E).  In contrast, mFFFA4-TDTS-
AAA was identified by the pT347/pS350 antiserum in an agonist-dependent manner (Figure 6E). 
Identification of mFFFA4-TDTS-AAA was reduced, however, compared to the wild type 
receptor, despite maintaining the specific target epitope. This may reflect that the peptide antigen 
sequence contains other residues of mFFA4 that may help define quaternary structure of this 
region.  
Interactions between mFFA4 and arrestin 3-Agonist-induced interactions between the 
mutant forms of mFFA4 and arrestin 3 (also sometimes designated β-arrestin 2) were then 
explored in a series of BRET studies performed in HEK293T cells co-expressing a form of 
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mFFA4-eYFP and arrestin 3 tagged with Renilla luciferase. In these studies stimulation of wild 
type FLAG-mFFA4-eYFP with TUG-891 produced a large, concentration-dependent (pEC50 = 
7.00 +/- 0.07 mean +/- SEM, n = 22) increase in BRET signal (Figure 7A). Removal of all the 
phosphorylation sites contained in clusters 1 and 2 at the C-terminal tail of mFFA4 (mFFA4-
ADAA-AAA) resulted in a substantial decrease in agonist-mediated interaction with arrestin 3 
(Figures 7A, B). In these experiments the maximal BRET signal obtained with mFFA4-ADAA-
AAA was only 19.7 +/- 1.2 % (n = 10) of that of wild type receptor (Figures 7A, B). Linked 
with the fact that mFFA4-ADAA-AAA showed no evidence of receptor phosphorylation (Figure 
6), this supports the notion that agonist-induced recruitment of arrestin 3 to mFFA4 is largely 
dependent on receptor phosphorylation. We next tested the relative contributions of each of 
cluster 1 and cluster 2 phosphorylation sites to the recruitment of arrestin 3. Conversion of serine 
residues within cluster 2 to alanine (mFFA4-TDTS-AAA) had a significant impact on the 
interaction of arrestin 3, reducing the maximal BRET signal to 31.9 +/-2.3% (n = 7) of that 
observed for the wild type receptor (Figure 7A, Table 1). In the case of cluster 1 (mFFA4-
ADAA-SSS), mutating the serine and threonine residues to alanine also resulted in a reduction in 
arrestin 3 recruitment (Emax 54.3 +/- 2.1 % (n = 12)) of that observed for the wild type receptor) 
but this was not to the same extent (p < 0.001) as that seen for the cluster 2 mutant (Figure 7A, 
Table 1). Equivalent conclusions as to the contribution of these two clusters to arrestin 3 
recruitment were drawn from kinetic BRET experiments carried out by treating the cells with a 
single maximal concentration of TUG-891 (10 µM) and recording the receptor-arrestin 3 
interaction over time (Figure 7B). Thus, it would appear that although cluster 1 and cluster 2 
provide equal contribution to the overall phosphorylation of mFFA4 in response to agonist 
activation (Figure 6) cluster 2 has a larger impact on the recruitment of arrestin 3.  
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Relationship between receptor phosphorylation, arrestin 3 recruitment and mFFA4 
internalization- Interactions with arrestins are frequently essential for agonist-induced receptor 
internalization (Luttrell and Gesty-Palmer, 2010; Marchese et al., 2008). To test the relationship 
between receptor phosphorylation, arrestin 3 recruitment and receptor internalization, both 
imaging of the cellular location of the eYFP tag (Figure 8A) and ELISA studies which measured 
removal of the N-terminal FLAG epitope tag from the surface of cells (Figure 8B) were used to 
define the extent of internalization of the FLAG-mFFA4-eYFP receptor constructs following 
exposure to TUG-891. Consistent with the canonical pathway, in which receptor phosphorylation 
promotes receptor-arrestin interaction, which in turn mediates receptor internalization, the 
variant mFFA4-ADAA-AAA, which contains alanines in place of all the serine/threonine 
residues in clusters 1 and 2 and interacted poorly with arrestin 3, showed a large reduction in 
TUG-891-mediated internalization (Figures 8A, B). Conversion to alanines of the cluster 2 
phosphorylation sites (mFFA4-TDTS-AAA) also inhibited agonist-mediated internalization, and 
to the same extent as mutation of all the phospho-acceptor sites.  In contrast, removal of cluster 1 
phosphorylation sites (mFFA4-ADAA-SSS had no effect on TUG-891-induced receptor 
internalization (Figures 8A, B). Hence, as observed for arrestin 3 recruitment (Figure 7), 
phosphorylation of residues within cluster 2 have a larger impact on receptor internalization than 
phosphorylation within cluster 1.  
Relationship between mFFA4 phosphorylation and coupling to ERK1/2 and protein 
kinase B/Akt- Agonist activation of FFA4 can result in downstream regulation of a number of 
signalling pathways. Although generally viewed as a receptor that couples selectively to Gq/G11 
family G proteins (Butcher et al., 2014; Milligan et al., 2015), there are also reports of key 
functions of the receptor that reflect engagement with pertussis toxin-sensitive Gi-family proteins 
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(Engelstoft et al., 2013). In CHO cells stably expressing FLAG-mFFA4-eYFP addition of TUG-
891 resulted in rapid phosphorylation of ERK1/2 MAP kinases. This effect was blocked 
completely by the selective Gq/G11 inhibitor YM-254890 (Canals et al., 2006; Nishimura et al., 
2010; Takasaki et al., 2004) (Figure 9A) indicating that mFFA4 coupling to ERK1/2 was 
transduced via Gq/G11 proteins. In contrast, mFFA4 activation of protein kinase B/Akt was 
independent of Gq/G11 proteins since this response was entirely unaffected by YM-254890 pre-
treatment (Figures 9B, C). This was the case whether Akt phosphorylation was measured via an 
HTRF-based assay (Figure 9B) or in immunoblots using a pAkt Ser473 antibody (Figure 9C).  
We next assessed, therefore, whether TUG-891 produced phosphorylation of protein kinase 
B/Akt via a Gi-family G protein-mediated cascade. However, pre-treatment of cells with 
pertussis toxin to cause ADP-ribosylation of Gi-family G proteins also did not affect this 
pathway (Figures 9D, 9E) and again this was the outcome whether using HTRF- (Figure 9D) or 
immunoblot-based assays (Figure 9E).  
It was possible that receptor phosphorylation-dependent pathways, rather than a canonical G 
protein-mediated pathway, might be responsible for coupling the mFFA4 to Akt signalling. The 
rapidly-induced peak of protein kinase B/Akt Ser473 phosphorylation was substantially lower for 
the combined cluster 1 and 2 mutant mFFA4-ADAA-AAA both in time-course experiments and 
in concentration-response studies employing TUG-891 (Figures 10 A, B) compared to wild type, 
indicating that receptor phosphorylation-dependent mechanisms do play a role in Akt signalling. 
Importantly, a similar reduction in peak AKT Ser473 phosphorylation was observed for the cluster 
1 mutant, mFFA4-ADAA-SSS (Figures 10A, B, Table 2). Notably, by contrast, the peak Akt 
Ser473 phosphorylation response for the cluster 2 mutant mFFA4-TDTS-AAA was equivalent to 
that of the wild type receptor (Figures 10A, B, Table 2). Thus, mFFA4 phosphorylation appears 
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to play a role in coupling the receptor to Akt activation and that amino acids within cluster 1 
(Thr347, Thr349 and Ser350) are the primary phosphorylation targets involved. By contrast, removal 
of serines and threonines in either cluster 1, cluster 2, or both groups did not uncouple mFFA4 
signalling to ERK1/2 (Figures 10C, D). This demonstrates that receptor phosphorylation, 
arrestin 3 recruitment, and receptor internalization, all of which are disrupted in these mutants, 
have no role in coupling mFFA4 to the ERK1/2 pathway. 
 
 
Discussion 
Many GPCRs fashion cell type specific signals despite being activated by the same 
ligand(s). Although this is poorly explored, these differences may reflect the relative prevalence 
of distinct G protein-mediated and non-canonical pathways that a receptor can couple to in 
different cell types. Importantly, such variation expands the diversity and utility of endogenous 
ligands and their receptors (Thompson et al., 2014) beyond the currently fashionable view of 
‘biased’ ligands that favor engagement with one signalling pathway over another in a single cell 
type (Luttrell et al., 2015; Violin et al., 2014). FFA4 is such a pleotropic GPCR (Milligan et al., 
2015), able to generate a range of physiological endpoints in different cell types by engaging 
distinct signalling pathways. For example, although FFA4-mediates elevation of Ca2+ via Gq/G11 
G proteins and hence promotes the release of incretin hormones, such as GLP-1, from 
enteroendocrine cells (Hirasawa et al., 2005), this receptor is also reported to regulate release of 
satiety promoting hormones from gut cells via activation of pertussis toxin-sensitive Gi-family G 
proteins (Engelstoft et al., 2013). Moreover, a number of anti-inflammatory effects of ω-3 fatty 
acids produced via macrophages are mediated by FFA4, reportedly via engagement with non-G 
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protein-dependent pathways involving recruitment of arrestin 3 and subsequent downstream 
interactions between TAB1 and TAK1 (Oh et al., 2010; Oh et al., 2014).  Although there may be 
opportunities to identify agonist ligands at FFA4 that display marked bias in stabilizing 
conformations of the receptor that allow differential engagement with Gq/G11 versus Gi G-
proteins or other pathways, current synthetic ligands of FFA4 are, in essence, carboxylic acid-
containing, fatty acid like molecules (Milligan et al., 2015).  Therefore, there is currently 
insufficient chemical diversity to hope to engage distinct signalling pathways with high 
selectivity compared to the endogenous ligands and to test this hypothesis directly.   
In the absence of such ligands our approach has been to determine the sites of 
phosphorylation and, by mutating these sites, generate a mutant receptor that is not 
phosphorylated and is therefore uncoupled from phosphorylation-dependent processes such as 
receptor interaction with arrestins and receptor internalization. We have previously described 
these receptor mutants as G protein biased as they predominately coupled to heterotrimeric G 
proteins over non-canonical pathways such as those mediated by arrestins (Kong et al., 2010). 
Here we employed mass spectrometry to determine that mFFA4 shows agonist-regulated 
phosphorylation within two specific clusters of serine/threonine residues (cluster 1 and cluster 2) 
located within the C-terminal tail.  Mutation of the observed phospho-acceptor amino acids to 
alanine resulted in a receptor that was fully resistant to agonist-induced 
phosphorylation. Interestingly, this receptor mutant coupled normally to the ERK1/2 pathway 
indicating that mFFA4 coupling to ERK1/2 was phosphorylation independent. Moreover, by 
employing an inhibitor of Gq/G11 proteins we were able to define that mFFA4 coupling to ERK 
was dependent on G protein signalling. This is in contrast to mFFA4 recruitment of arrestin 3, 
mFFA4 internalization and Akt activation which were all regulated by mFFA4 phosphorylation. 
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Thus, we were able to de-convolute the mFFA4 signalling responses that lay downstream of G 
protein coupling and mFFA4 phosphorylation.  
 One of the primary functions of GPCR phosphorylation is to promote the interaction of 
the receptor with members of the arrestin-adaptor protein family (arrestin 1-4) (Reiter and 
Lefkowitz, 2006). Although the extent to which phosphorylation increases the affinity of the 
activated receptor for an arrestin depends on the receptor subtype (see; (Tobin, 2008)) we show 
here that agonist-mediated recruitment of arrestin 3 to mFFA4 was almost totally dependent on 
phosphorylation of residues at the C-terminal tail of the receptor. In this respect mFFA4 behaves 
in a very similar manner to human FFA4 (Butcher et al., 2014). Also consistent with human 
FFA4, the phospho-acceptor sites on mFFA4 appeared in two clusters, cluster 1 (Thr347, Thr349 
and Ser350) and cluster 2 (Ser357 and Ser361). Based on incorporation of [32P] orthophosphate each 
cluster contributed approximately equally to the overall phosphorylation of the receptor in 
response to agonist, however, phosphorylation at cluster 2 had a larger impact on arrestin 
3recruitment. These data point towards site-specific roles for phosphorylation of mFFA4 and 
argues against the concept that phosphorylation at multiple sites at the C-terminal tail simply 
adds bulk negative charge which drives arrestin interaction, as has been suggested might be the 
case for rhodopsin (Ohguro et al., 1993).  
Our study extended the analysis of the site-specific role of phosphorylation by 
consideration of other phosphorylation-dependent processes. This included receptor 
internalization that similarly was affected more by removal of the phosphorylation sites in cluster 
2 than cluster 1. This correlates with reduced interaction with arrestin 3 seen in the cluster 2 
mutant and is consistent with the known role of arrestins in driving receptor internalization 
(Shenoy and Lefkowitz, 2011). The relationship between receptor phosphorylation and the 
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activation of Akt was, however, more complex. Here the peak Akt response was significantly 
reduced by a mutant mFFA4 where all the phospho-acceptor sites were removed, indicating an 
important regulatory role of phosphorylation in this response. Selective removal of cluster 2 
phospho-acceptor sites did not, however, significantly affect the Akt response. In contrast, 
removal of phospho-acceptor sites within cluster 1 had as large an effect on the Akt response as 
removal of all the phospho-acceptor sites in mFFA4. Therefore, these data further support the 
hypothesis that different sites of phosphorylation at the C-terminus of mFFA4 having different 
signalling outcomes. 
As the cluster 1 mutant, despite showing poor interaction with arrestin 3, still activated 
Akt fully it might be concluded that arrestin 3 plays only a minor role in the activation of this 
pathway by mFFA4. However, neither blockade of Gq/G11 or Gi-G protein family interactions 
with the receptor affected this signal. Moreover, as a downstream measure of mFFA4 activation, 
it would be expected that regulation of Akt would show a significant degree of amplification and, 
therefore, substantially reduced interaction with arrestin 3 is compatible with maintenance of a 
level of signal generation. This is a common feature in ‘knock-down’ studies where a non-linear 
relationship between the degree of protein reduction and effect is often seen and is to be 
expected.  Thus our data can be interpreted to indicate that phosphorylation at cluster 2 regulates 
Akt signalling in an arrestin-dependent manner. Moreover, a number of other receptors have also 
been shown to activate the Akt pathway in an arrestin-dependent manner (Cianfrocca et al., 
2010; Kendall et al., 2014).  Given the possibility that mFFA coupling to Akt is phosphorylation 
and arrestin 3 dependent it is possible that phosphorylation at either cluster 1 or 2 induces 
distinct and differential conformations of arrestin 3 and that these mediate different signalling 
outcomes from the arrestin. Assessing this hypothesis will be an important challenge for the 
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future. In the case of Akt activation, it may be that phosphorylation within cluster 2 induces an 
arrestin conformation that drives Akt activation. Removal of phospho-acceptor sites in cluster 2 
will thereby prevent arrestin from adopting a conformation that mediates Akt signalling. We, and 
others, have suggested that the multi-site phosphorylation of GPCRs might represent a barcode 
that determines receptor-signalling outcomes and that by differential regulation of the 
phosphorylation barcode different signalling outcomes can be achieved (Butcher et al., 2011; 
Nobles et al., 2011; Tobin et al., 2008).  It is possible that different phosphorylation barcodes 
mediate different arrestin conformations and that this results in different arrestin-dependent 
signalling (Nobles et al., 2011). Although it is now clear that arrestin adopts an active 
conformation on interaction with receptors (Zhuo et al., 2014) and that a recent crystal structure 
of arrestin in complex with a phosphorylated C-terminal tail peptide of a GPCR provides atomic 
level detail of the active arrestin conformation (Shukla et al., 2013) it is not yet clear whether 
differential phosphorylation can result in different active conformational states. Our data does, 
however, support the hypothesis that differential receptor phosphorylation can result in different 
signalling outcomes. In the case of mFFA4 it would appear that phosphorylation within cluster 1 
can impact preferentially on arrestin interaction and receptor internalization whilst 
phosphorylation within cluster 2 has less impact on arrestin recruitment and internalization but, 
rather, preferentially regulates Akt signalling.   
Our studies clearly predict that identification or design of novel mFFA4 ligands that drive 
differential phosphorylation at cluster 1 and cluster 2 would show differential coupling to 
phosphorylation-dependent processes that include arrestin recruitment, receptor internalization 
and Akt signalling. In this way an mFFA4 ligand that can modulate the site-specific 
phosphorylation of residues within cluster 1 and 2 would have a highly refined signalling profile 
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and, as a consequence, might activate a restricted number of physiological responses compared 
to a ligand that activated non-selectively both phosphorylation-dependent and independent 
signalling. This may be very important in the development of therapeutic compounds that target 
FFA4, for example to regulate glycaemia in type II diabetes (Milligan et al., 2015; Oh et al., 
2014; Sekiguchi et al., 2015; Watterson et al., 2014), where it is desirable to activate those 
pathways that mediate therapeutically beneficial outcomes over pathways that lead to 
adverse/toxic responses.  Thus, the study presented here might provide the framework to develop 
mFFA4 biased ligands that specifically promote signalling with improved therapeutic potential.  
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FIGURE LEGENDS 
 
Figure 1: Murine FFA4 becomes phosphorylated in an agonist-dependent and sustained 
manner 
Flp-InTM CHO cells stably expressing mFFA4-HA were labelled with [32P]-orthophosphate and 
treated for 5 minutes (A-C) or for varying times (D-F) with vehicle (-) or the indicated 
concentrations of α-linolenic acid (αLA) or TUG-891. Following anti-HA immunoprecipitation 
samples were resolved by SDS-PAGE and subjected to autoradiography (A, D). Such 
autoradiograms were quantified by densitometry (C, F). Structure of TUG-891 is shown (G). 
Data are means +/- SEM. Significantly greater than vehicle treated **p < 0.01, *** p < 0.001. 
Similar levels of the receptor construct in each sample was demonstrated in anti-HA 
immunoblots (B, E). WB = western blot, Mono = monoclonal. 
 
Figure 2: Mass spectrometry analysis of sites of agonist-promoted phosphorylation in 
mFFA4 
CHO Flp-InTM cells stably expressing C-terminally HA-tagged mFFA4 and treated with TUG-
891 (10 μM, 5 min) were used to immunoprecipitate and then digest the receptor for analysis 
using mass spectrometry. A-E representative mass spectra and associated fragmentation tables 
are shown that cover the five phosphorylated residues, Thr347, Thr349, Ser350 Ser357, Ser361, 
identified in various experiments. F shows a cartoon of mFFA4 with the sequence from the 
conserved NPXXY motif (NPILY in this receptor) at the bottom of transmembrane domain VII 
to the C-terminal tail, with amino acids denoted by the ‘one letter’ code. Amino acids that were 
identified as being phosphorylated are in bold.  G provides a summary of the overall data set. 
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Figure 3: Generation and characterization of phospho-state specific mFFA4 antibodies 
Antisera were generated against peptides incorporating either only phospho-Ser350 (A, D) or both 
phospho-Thr347 and phospho-Ser350 (B, E). Affinity purified antibodies were used to assess the 
phosphorylation status of FLAG-mFFA4-eYFP following treatment with vehicle or TUG-891 
(10 µM, 5 min). Parallel immunoblots with an anti-GFP antiserum defined equal loading and 
levels of receptor expression in each sample (C, F). Confirmation that the phospho-Thr347/Ser350 
and phospho-Ser350 antibodies were indeed phospho site-specific was produced by pre-treating 
samples prior to resolution on SDS-PAGE with calf intestinal alkaline phosphatase (CIAP) (A, 
B). The phospho-specific antibodies displayed marked species specificity (D-F). Although 
human FFA4 also becomes phosphorylated in response to addition of TUG-891 and we have 
previously described phospho-specific antibodies able to recognise this protein (ref 26), neither 
of the mFFA4 phospho-specific antibodies was able to identify the phosphorylated human 
receptor (D, E). Immunoblots with anti-GFP/eYFP confirmed that the human receptor was 
expressed at similar levels (F). IP = immunoprecipitation, WB = western blot. Mono = 
monoclonal, Poly = polyclonal. 
 
Figure 4: Identification of agonist regulation of mFFA4 phosphorylation status using 
phosphorylation site specific antibodies 
Flp-InTM T-RExTM 293 cells were induced to express FLAG-mFFA4-eYFP by addition of 
doxycycline. Lysates of cells exposed to the indicated concentrations of TUG-891 for 5 min 
were resolved by SDS-PAGE and phosphorylated receptors detected by immunoblotting with the 
phospho-Thr347/Ser350 antibodies (A). Experiments akin to A were performed using combinations 
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of the FFA4 agonist TUG-891 and the FFA4 antagonist compound 39 (Sparks et al., 2014) 
Samples were subsequently immunoblotted with the phospho-Thr347/Ser350 (left hand side) or 
the phospho-Ser350 antibodies (right hand side) (B). Cells as in A were exposed to the indicated 
concentrations of the fatty acid ligands DHA or αLA or the synthetic agonist TUG-891. 
Phosphorylated receptor was detected using phospho-Thr347/Ser350 antibodies (C). Structure of 
compound 39 is shown (D). 
 
Figure 5: Phosphorylated mFFA4 is identified in immunocytochemical studies 
Flp-InTM CHO cells transfected to express FLAG-mFFA4-eYFP (A-C) or parental cells (D) were 
grown on coverslips. Those expressing FLAG-mFFA4-eYFP were treated with TUG-891 (10 
μM, 10 min) (A), vehicle (B) or compound 39 (10 μM, 60 min) (C). After fixation cells were 
treated with the phospho-Thr347/Ser350 antibodies and with DAPI to identify cell nuclei. Blue = 
DAPI, Green = eYFP, Red = phospho-Thr347/Ser350 antibodies. The merged images (right hand 
panels) illustrate co-localization of eYFP-tagged receptor and the phospho-site specific 
antibodies (A, B). Note the enhanced staining with the phospho-receptor specific antibodies after 
treatment with TUG-891 (A versus B) and the reduction in basal antibody staining after 
treatment with compound 39 (C versus B). 
 
Figure 6: Mutagenesis studies define two clusters of amino acids that become 
phosphorylated in response to TUG-891 
The C-terminal sequence of mFFA4 is shown using the amino acid one letter code. Aliphatic 
hydroxy amino acids (serine and threonine) in this region that are potential targets for 
modification by phosphorylation are in bold. Designation of variants in which clusters of these 
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residues were mutated to alanine is shown, and in the sequence these changes are noted (A).   
Wild type FLAG-mFFA4-eYFP and each of the indicated mutants were expressed stably in Flp-
InTM CHO cells. [32P]-orthophosphate labelling and incorporation of this into the forms of the 
receptor (B) with or without treatment with TUG-891 for 5 min was performed as in Figure 1. 
Parallel immunoblotting studies using anti-GFP/eYFP indicated that each form of the receptor 
was expressed to similar levels (C). Quantification of the extent of incorporation of [32P] into the 
receptor was performed as in Figure 1 (D). Different from wild type; * p < 0.05. E, F. Cells 
expressing mFFA4-eYFP, mFFA4-TDTS-AAA, mFFA4-ADAA-SSS, or mFFA4-ADAA-AAA 
were treated for 5 min with TUG-891 and immunoblots performed on cells lysates using the 
phospho-Thr347/Ser350 (E) or anti-FLAG (F) antisera. WB = western blot, Poly = polyclonal. 
  
Figure 7: Elimination of C-terminal hydroxyl amino acids from mFFA4 compromise 
agonist-induced interaction with arrestin 3 
BRET studies were performed in HEK293T cells transfected to co-express arrestin 3-Renilla 
luciferase and each of wild type FLAG-mFFA-eYFP , mFFA4-ADAA-SSS, mFFA4-TDTS-
AAA or mFFA4-ADAA-AAA. Following addition of the indicated concentrations of TUG-891 
for 5 minutes, interaction was recorded (A). Although the alterations to the receptor sequence did 
not affect the potency of TUG-891 each of the three variants produced a smaller effect than wild 
type. Differences between the individual mutants in terms of maximal signal were also 
significant as noted, *** p < 0.001.  Similar studies were performed, but following addition of 
TUG-891 (10 μM) interactions were followed over time (B). Representative traces are shown. 
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Figure 8: Elimination of C-terminal hydroxyl amino acids from mFFA4 compromises 
agonist-induced internalization of the receptor 
N-terminally FLAG and C-terminally e-YFP-tagged forms of wild type mFFA, mFFA4-TDTS-
AAA, mFFA4-ADAA-SSS, or mFFA4-ADAA-AAA were expressed stably in Flp-InTM T-
RExTM 293 cells. Following doxycycline induced expression of the receptor constructs for 24 
hours cells were challenged with vehicle (0 min) or 10 μM TUG-891 (60 min). A. Cells were 
imaged to identify the location of eYFP. Representative images of groups of cells are shown. B. 
Cell surface ELISA assays were performed using an anti-FLAG antibody to detect cell surface 
receptor on non-permeabilized cells treated as in A with vehicle (0 min) or 10 μM TUG-891 (60 
min). Data are means +/- SEM of triplicate data points from a single experiment, representative 
of four. Internalization of mFFA4-ADAA-SSS in response to the agonist was unaffected 
compared to wild type mFFA4, whilst internalization of both mFFA4-TDTS-AAA and mFFA4-
ADAA-AAA was substantially reduced. *** p < 0.001. 
 
Figure 9: Signalling of mFFA4 to pAkt Ser473 is G protein-independent 
Flp-InTM CHO cells expressing FLAG-mFFA4-eYFP were used to assess the potential 
contribution of Gq/G11 (A-C) or Gi-family G proteins (D-E) to TUG-891-mediated regulation of 
pERK1/2 (A) or pAkt Ser473 (B-E) phosphorylation in either HTRF (A, B, D) or immunoblotting 
(C, E) studies. In certain studies cells were pre-treated with the Gq/G11- inhibitor YM-254890 
(A-C) or the Gi-inhibitor pertussis toxin (PTX) (D-E). Effects of TUG-891 +/- inhibitors were 
assessed.  Although YM-254890 fully blocked the effect of TUG-891 in pERK1/2 assays (A), it 
had no effect on pAkt Ser473 (B, C) whilst pertussis toxin also did not modify TUG-891 
regulation of this signal end point (D, E). *** p < 0.001, ns  = not significantly different. 
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Figure 10: Signalling of mFFA4 to pAkt Ser473 is dependent upon the capacity for and 
location of phosphorylation within the receptor 
pAkt Ser473 (A, B) or pERK1/2  (C, D) was assessed in HTRF assays in Flp-InTM CHO cells 
expressing mFFA4-eYFP (circles), mFFA4-TDTS-AAA-eYFP (triangles), FLAG mFFA4-
ADAA-SSS-eYFP (squares), or FLAG mFFA4-ADAA-AAA-eYFP (inverted triangles). Effects 
of TUG-891 (10 μM) for varying times (A, C) or of varying concentrations of the agonist for 5 
minutes (B, D) were assessed. 
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Table 1:  
Concentration response and kinetic profiles of TUG-891 at the mFFA4-WT and mutant 
receptors in an arrestin-3 BRET assay. Data represent the mean ± S.E.M. of at least five 
independent experiments. 
 pEC50 Emax n Plateau t1/2 n 
 
mFFA4-WT 
 
 
7.0 +/- 
0.05 
 
100 
 
28 
 
396.5 +/- 29.2 
 
41.8 +/- 1.4 
 
6 
mFFA4-
ADAASSS 
 
6.9 +/- 
0.04 
54.3 +/- 2 13 191.2 +/- 17.2 28.4 +/- 1.7 6 
mFFA4-
TDTSAAA 
 
6.8 +/- 0.1 31.7 +/- 2 9 87.4 +/- 8.3 47.9 +/- 1.9 7 
mFFA4-
ADAAAAA 
6.8 +/- 0.1 19.7 +/- 1 10 87.39 +/- 11 25.9 +/- 5.1 5 
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Table 2:   
Potency (pEC50), and relative efficacy (Emax) of TUG-891 at the mFFA4-WT and mutant 
receptors in pERK1/2 and pAkt (Ser473) assays. Values represent the mean ± S.E.M. from 
three independent experiments performed in triplicate. 
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